Your Health, We Care
The combination of lazertinib and amivantamab is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as confirmed by an FDA-approved test.
FDA，2024.08
